FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972265611> ?p ?o ?g. }

• W1972265611 endingPage "819" @default.
• W1972265611 startingPage "809" @default.
• W1972265611 abstract "Antigen-specific immunotherapy and vascular disrupting agents, such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA), have emerged as attractive approaches for the treatment of cancers. In the current study, we tested the combination of DMXAA treatment with therapeutic human papillomavirus type 16 (HPV-16) E7 peptide-based vaccination for their ability to generate E7-specific CD8+ T-cell immune responses, as well as their ability to control E7-expressing tumors in a subcutaneous and a cervicovaginal tumor model. We found that the combination of DMXAA treatment with E7 long peptide (amino acids 43–62) vaccination mixed with polyriboinosinic:polyribocytidylic generated significantly stronger E7-specific CD8+ T-cell immune responses and antitumor effects compared with treatment with DMXAA alone or HPV peptide vaccination alone in the subcutaneous model. Additionally, we found that the DMXAA-mediated enhancement of E7-specific CD8+ T-cell immune responses generated by the therapeutic HPV peptide-based vaccine was dependent on the timing of administration of DMXAA. Treatment with DMXAA in tumor-bearing mice was also shown to lead to increased dendritic cell maturation and increased production of inflammatory cytokines in the tumor. Furthermore, we observed that the combination of DMXAA with HPV-16 E7 peptide vaccination generated a significant enhancement in the antitumor effects in the cervicovaginal TC-1 tumor growth model, which closely resembles the tumor microenvironment of cervical cancer. Taken together, our data demonstrated that administration of the vascular disrupting agent, DMXAA, enhances therapeutic HPV vaccine-induced cytotoxic T-lymphocyte responses and antitumor effects against E7-expressing tumors in two different locations. Our study has significant implications for future clinical translation. Vascular disrupting agents such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) have emerged as a new class of potential anticancer drugs that selectively destroy the established tumor vasculature and shut down blood supply to solid tumors. In this study, Zeng and colleagues test the combination of DMXAA treatment with E7 long peptide vaccination mixed with poly(I:C) to enhance cellular immunity against E7-expressing tumors in mice." @default.
• W1972265611 created "2016-06-24" @default.
• W1972265611 creator A5017307827 @default.
• W1972265611 creator A5021637798 @default.
• W1972265611 creator A5025082076 @default.
• W1972265611 creator A5062803843 @default.
• W1972265611 creator A5067516105 @default.
• W1972265611 creator A5085663287 @default.
• W1972265611 creator A5087272361 @default.
• W1972265611 date "2011-07-01" @default.
• W1972265611 modified "2023-10-14" @default.
• W1972265611 title "Control of Cervicovaginal HPV-16 E7-Expressing Tumors by the Combination of Therapeutic HPV Vaccination and Vascular Disrupting Agents" @default.
• W1972265611 cites W1522781268 @default.
• W1972265611 cites W1751493734 @default.
• W1972265611 cites W1970464571 @default.
• W1972265611 cites W1978146796 @default.
• W1972265611 cites W1986716191 @default.
• W1972265611 cites W1986847770 @default.
• W1972265611 cites W1987350137 @default.
• W1972265611 cites W1997487577 @default.
• W1972265611 cites W2007245430 @default.
• W1972265611 cites W2007725988 @default.
• W1972265611 cites W2018604730 @default.
• W1972265611 cites W2020830322 @default.
• W1972265611 cites W2035490072 @default.
• W1972265611 cites W2041939445 @default.
• W1972265611 cites W2062078150 @default.
• W1972265611 cites W2069280729 @default.
• W1972265611 cites W2071244674 @default.
• W1972265611 cites W2088803858 @default.
• W1972265611 cites W2090032302 @default.
• W1972265611 cites W2095514456 @default.
• W1972265611 cites W2096031499 @default.
• W1972265611 cites W2096866753 @default.
• W1972265611 cites W2098491904 @default.
• W1972265611 cites W2100745065 @default.
• W1972265611 cites W2114460942 @default.
• W1972265611 cites W2114813165 @default.
• W1972265611 cites W2115760452 @default.
• W1972265611 cites W2126246455 @default.
• W1972265611 cites W2136236728 @default.
• W1972265611 cites W2141892585 @default.
• W1972265611 cites W2143411828 @default.
• W1972265611 cites W2150436558 @default.
• W1972265611 cites W2155358182 @default.
• W1972265611 cites W2169128948 @default.
• W1972265611 doi "https://doi.org/10.1089/hum.2010.071" @default.
• W1972265611 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3135274" @default.
• W1972265611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21128743" @default.
• W1972265611 hasPublicationYear "2011" @default.
• W1972265611 type Work @default.
• W1972265611 sameAs 1972265611 @default.
• W1972265611 citedByCount "32" @default.
• W1972265611 countsByYear W19722656112012 @default.
• W1972265611 countsByYear W19722656112013 @default.
• W1972265611 countsByYear W19722656112014 @default.
• W1972265611 countsByYear W19722656112015 @default.
• W1972265611 countsByYear W19722656112016 @default.
• W1972265611 countsByYear W19722656112017 @default.
• W1972265611 countsByYear W19722656112019 @default.
• W1972265611 countsByYear W19722656112020 @default.
• W1972265611 countsByYear W19722656112021 @default.
• W1972265611 crossrefType "journal-article" @default.
• W1972265611 hasAuthorship W1972265611A5017307827 @default.
• W1972265611 hasAuthorship W1972265611A5021637798 @default.
• W1972265611 hasAuthorship W1972265611A5025082076 @default.
• W1972265611 hasAuthorship W1972265611A5062803843 @default.
• W1972265611 hasAuthorship W1972265611A5067516105 @default.
• W1972265611 hasAuthorship W1972265611A5085663287 @default.
• W1972265611 hasAuthorship W1972265611A5087272361 @default.
• W1972265611 hasBestOaLocation W19722656112 @default.
• W1972265611 hasConcept C147483822 @default.
• W1972265611 hasConcept C154317977 @default.
• W1972265611 hasConcept C167672396 @default.
• W1972265611 hasConcept C195616568 @default.
• W1972265611 hasConcept C202751555 @default.
• W1972265611 hasConcept C203014093 @default.
• W1972265611 hasConcept C22070199 @default.
• W1972265611 hasConcept C2776789287 @default.
• W1972265611 hasConcept C2777701055 @default.
• W1972265611 hasConcept C502942594 @default.
• W1972265611 hasConcept C55493867 @default.
• W1972265611 hasConcept C71924100 @default.
• W1972265611 hasConcept C86803240 @default.
• W1972265611 hasConcept C8891405 @default.
• W1972265611 hasConceptScore W1972265611C147483822 @default.
• W1972265611 hasConceptScore W1972265611C154317977 @default.
• W1972265611 hasConceptScore W1972265611C167672396 @default.
• W1972265611 hasConceptScore W1972265611C195616568 @default.
• W1972265611 hasConceptScore W1972265611C202751555 @default.
• W1972265611 hasConceptScore W1972265611C203014093 @default.
• W1972265611 hasConceptScore W1972265611C22070199 @default.
• W1972265611 hasConceptScore W1972265611C2776789287 @default.
• W1972265611 hasConceptScore W1972265611C2777701055 @default.
• W1972265611 hasConceptScore W1972265611C502942594 @default.
• W1972265611 hasConceptScore W1972265611C55493867 @default.
• W1972265611 hasConceptScore W1972265611C71924100 @default.
• W1972265611 hasConceptScore W1972265611C86803240 @default.

• next